

2.0 RESPONSE

2.1 STATUS OF THE CLAIMS

Claims 1-57 were pending at the time of the amendment.

Claims 2, 4, 5, and 8 are amended herein.

Claims 1-57 remain pending in the case.

2.2 SUPPORT FOR THE CLAIMS

Complete support for each of the claims as amended herein is provided by the specification and original claims as filed. Support for the phrase "A2b receptor" is found at least on page 18, in Fig. 7, and Example 5.2, particularly in Table 3. Support for the phrase "IGF-1 receptor" is found at least on pages 15, 75, and 78, and Tables 7 and 8. Applicants certify that no new matter has been introduced as a result of the accompanying amendment.

3.0 CONCLUSION

Applicants believe that no fee is due with the submission of this amendment before first action on the merits. However, if any fee is due for any reason, the Commissioner is authorized to deduct the fee as described in paragraph 1 of this paper. Should the Examiner have any questions concerning this amendment, a telephone call to the undersigned Applicants' representative would be appreciated.

Respectfully submitted,



Mark D. Moore, Ph.D.
Reg. No. 42,903
Agent for Applicants

Date: August 19, 2005

Haynes and Boone, LLP
901 Main Street
Suite 3100
Dallas, Texas
(214) 5000